BPC-157

Body Protection Compound-157 / Pentadecapeptide

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It's one of the most talked-about research peptides for soft-tissue repair — studied for tendon, ligament, muscle, gut and nerve healing. This guide breaks down how BPC-157 actually works, what the research does and doesn't show, how it's dosed in the literature, its safety profile and legal status, and how it compares to TB-500 — honestly, without the hype.

How BPC-157 works

BPC-157's headline mechanism is angiogenesis — the growth of new blood vessels into damaged tissue. In research models it upregulates vascular endothelial growth factor (VEGF) and activates the VEGFR2 receptor, kicking off the PI3K/Akt and MAPK/ERK signaling cascades that drive new capillary formation. More blood vessels means more oxygen, nutrients and repair cells reaching an injury.

It also acts fast on the nitric-oxide (NO) system. Studies show BPC-157 phosphorylates endothelial nitric oxide synthase (eNOS) within about 30 minutes and disrupts the Cav-1–eNOS inhibitory complex, directly increasing nitric-oxide production in a dose-dependent way — which supports blood flow and vascular tone.

At the tissue level, BPC-157 has been shown to upregulate the growth-hormone receptor in tendon fibroblasts and to boost collagen synthesis and fibroblast activity. In a rat Achilles-tendon model it produced a ~2.3-fold increase in vascular density in the repair zone by day 14. Together these effects explain why it's researched across tendon, ligament, muscle, bone and gut tissue.

What the research shows — benefits by use case

Tendon, ligament & joint. The strongest preclinical signal. Animal models show faster, stronger tendon-to-bone and ligament healing, and a small human pilot in knee pain reported meaningful relief. This is the use case BPC-157 is best known for.

Gut & GI. BPC-157 originates from gastric juice, and much of its earliest research is on the gut — protecting against ulcers, supporting intestinal-barrier integrity ('leaky gut'), and healing GI lesions in animal models. This is why it's frequently used orally for gut goals.

Muscle & nerve. Preclinical work suggests accelerated muscle-crush recovery and peripheral-nerve regeneration, likely downstream of the same angiogenic and growth-factor effects.

Important honesty check: the overwhelming majority of this evidence is from animal studies. It's promising and mechanistically coherent, but it is not the same as proven human efficacy — see the next section.

The honest state of human evidence

Despite decades of striking animal data, robust human evidence for BPC-157 is still very thin. As of 2026 only a handful of small human pilot studies have been published — on the order of a few dozen total subjects — covering interstitial cystitis (bladder), knee pain, and an early IV-safety study. A larger Phase I trial begun in 2015 was never published.

Bottom line: BPC-157 is a genuinely promising research compound, not a proven therapy. Anyone considering it should treat it as experimental and weigh that limited human data honestly.

BPC-157 dosing (research reference)

Across the research and practitioner literature, BPC-157 is most commonly referenced in the 250 mcg–1 mg per day range, often split into one or two doses and run in cycles of roughly 4–12 weeks. Injectable (subcutaneous) is the most studied route, frequently placed near the site of injury; oral is popular specifically for gut-related goals, and nasal forms also exist.

BPC-157 ships as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water before injection. Use the reconstitution calculator above to convert your vial size and target dose into exact insulin-syringe units. None of this is dosing advice — it's a summary of what the research references, for educational purposes only.

Safety & side effects

In the animal literature and the small human pilots to date, BPC-157 has generally been reported as well tolerated, with few acute side effects noted. That said, the honest caveat is we lack long-term human safety data. Because its core mechanism is angiogenesis, there is a theoretical discussion around whether promoting blood-vessel growth is desirable in every individual context. Product quality also varies widely in the research-chemical market — purity, correct sequence and sterility are real concerns, so third-party testing and a Certificate of Analysis matter.

BPC-157 vs TB-500 — and stacking

BPC-157 and TB-500 are the two pillars of the 'healing peptide' world and are often discussed together. BPC-157 leans toward local, vascular and gut repair via VEGF and nitric oxide; TB-500 (a fragment of thymosin beta-4) works more systemically by regulating actin to drive cell migration and flexibility. Many protocols run them together — that combination is the basis of the popular Wolverine blend — on the theory that they hit complementary arms of the healing process.

Legal & regulatory status

In 2023 the FDA placed BPC-157 in Category 2 of its bulk-drug-substance review, meaning it cannot currently be legally compounded by pharmacies for human use — citing limited safety data and manufacturing/immunogenicity concerns. Its status remains under active review. For that reason BPC-157 is sold and discussed as a research compound (research use only), not an approved medicine. Always follow the laws in your jurisdiction.

Where to get BPC-157

BPC-157 is sold in 3 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.

BPC-157 reconstitution calculator

The evidence for BPC-157

Graded by what exists behind each claim.

✅ Clinically validated

• No completed randomized human trial, and it is worth being exact about why. BPC-157 is a synthetic fragment of a gastric protein; it has no patentable composition worth the cost of a phase 3, and no sponsor has taken one on. A trial has been registered but there is no published human efficacy result.
• The FDA moved it to the bulk-substances category 2 list in 2023, which restricts compounding — a regulatory judgement about the absence of data, not a finding of harm.

📊 Correlative data

• One of the most-used peptides in existence and the anecdotal record is correspondingly enormous, particularly for tendon, ligament and gut complaints. It is also the clearest case in the Vault of why anecdote is a weak instrument: soft-tissue injuries and gut flares both improve on their own, so a compound taken during recovery gets the credit either way.
• Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.

🧪 Theoretical / extrapolated

• The animal literature is unusually broad and unusually consistent — accelerated tendon-to-bone healing, protection against NSAID-induced gut damage, and effects on the nitric-oxide system across many rodent models from largely one research group.
• The proposed mechanism is upregulation of VEGF-driven angiogenesis and growth-factor receptor expression at the injury site. That same angiogenic mechanism is the reason for the one caution that actually matters here: anything that reliably grows new blood vessels is a question mark in the presence of an undiagnosed tumor, and nobody has studied that in humans.

What community dosing logs are worth →

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What BPC-157 actually does

BPC-157 is fifteen residues long — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a 1419 Da peptide with four prolines in the first eight positions and no cysteine anywhere. It is described everywhere as a fragment of a protein found in human gastric juice, and that description is doing more work than it can carry: no parent protein has ever been isolated, sequenced and deposited. What exists is a synthetic peptide with a proposed origin story. Say it plainly, because the origin story is most of what the marketing rests on.

There is no cloned BPC-157 receptor. Not an orphan one, not a candidate one. For a compound sold on the strength of hundreds of rodent papers that is a genuinely unusual position, and it changes what counts as a mechanism here: you cannot write "binds X, activates Y", so the honest mechanism is the one experiment that measured a signaling event and named the proteins in it.

That experiment is Hsieh 2020, and it is the most specific thing anybody has shown about this molecule. Isolated rat aorta. BPC-157 produced concentration-dependent vasodilation. The relaxation was endothelium-dependent — strip the endothelium and it goes — and it was abolished by L-NAME, the nitric oxide synthase inhibitor, and by hemoglobin, which mops up free NO. So the effector is nitric oxide made by the endothelial cell.

Then they asked how. In rat vascular endothelial cells BPC-157 increased phosphorylation of Src, of caveolin-1 and of eNOS; a Src inhibitor abolished all three; and co-immunoprecipitation showed BPC-157 reduced the amount of eNOS bound to caveolin-1. That last result is the mechanism, and it is worth understanding rather than repeating. In a resting endothelial cell, eNOS sits in a caveola physically clamped by caveolin-1, which holds it inactive. Src-mediated phosphorylation of caveolin-1 loosens the clamp and eNOS is released to make NO. BPC-157 is not adding nitric oxide and it is not adding substrate. It is releasing an enzyme the cell already has from the brake the cell already applies.

Two consequences follow that nobody selling this peptide mentions. First, a mechanism that runs through eNOS is a systemic mechanism — endothelium is everywhere, and the argument for injecting "near the injury" is a delivery argument, not a mechanistic one. Second, this is the same final common path as nitrates and the same downstream signal PDE5 inhibitors amplify, which is where the interaction question on this page comes from.

The angiogenesis story sits one level further down. NO drives VEGF signaling and endothelial migration, and Brcic 2009 reported that BPC-157 modulated angiogenesis in rat muscle and tendon healing — which makes the growth of new vessels a consequence of the NO step rather than a separate action. The Zagreb group's own synthesis of the wound literature reaches the same shape Seiwerth 2021.

Cell, rodent, human — and where it stops

Step one, in a dish, and this is the strongest link. Isolated rat aorta and rat vascular endothelial cells, Src / caveolin-1 / eNOS phosphorylation measured directly, the NO dependence proved twice over with two different blockers Hsieh 2020. This is real, reproducible pharmacology and it is why the compound deserves a serious page.

Step two, in rodents, and this is where the volume is. Rat tendon and muscle healing with angiogenesis as the readout Brcic 2009; skin, muscle, tendon, ligament, bone, cornea, nerve and gut models collected in Seiwerth 2021; striated, smooth and cardiac muscle in Staresinic 2022; NSAID and alcohol gut lesions in Sikiric 2020; major-vessel occlusion and ischemia-reperfusion in Sikiric 2022; spinal cord injury in Perovic 2022. The breadth is the argument people make for it.

The breadth is also the first obstacle, and it is a real one. Very nearly all of that literature comes from one laboratory in Zagreb and its collaborators, working over roughly three decades. That is not an accusation of anything; it is a statement about independent replication, which is the property that makes a rodent result predictive. A compound with 200 papers from one group and 2 from anybody else is in a weaker evidential position than one with 20 papers from ten groups, and the raw paper count hides that.

Step three, pharmacokinetics, and it contradicts this page's own card. The one published PK study reports an elimination half-life under 30 minutes He 2022. The card at the top of this page says ~4 hrs systemic. Those cannot both be right, and the measured one is the one with a method section. Thirty minutes is not a problem for the compound — a signaling peptide that releases eNOS from caveolin-1 does not need to persist to have done something — but it does change the dosing logic completely, and it is why twice daily is the pattern people converge on by trial and error.

Step four, in humans: no completed efficacy trial. Not a small one, not a negative one. There is no published randomized human result for tendon, gut, or anything else. The compound has no patentable composition worth a phase 3, which explains the absence without excusing it. In 2023 the FDA placed BPC-157 in the bulk drug substances category 2 list, restricting compounding — a regulatory judgement about missing data, not a finding of harm.

The obstacles, named one at a time. (1) Single-group literature. (2) Rodent injury models are acute, clean, surgically created lesions in young animals; a 40-year-old's chronic tendinopathy is a degenerative lesion with a different biology. (3) The oral form sold alongside the injectable has no published bioavailability figure at all — a 15-residue peptide with a free N-terminal glycine is a substrate for brush-border aminopeptidases, and the burden of proof that anything crosses intact has not been met. (4) The vasodilation work is aorta, not tendon; the tissue where the effect matters has never had the pathway measured in it.

BPC-157 pharmacokinetics — how much of it actually gets in

The card says ~4 hours. The literature says under 30 minutes He 2022. Here is the arithmetic that decides which to believe, and what it means for the three forms this page sells.

What degrades it. Fifteen residues, all-L, no ring, no D-amino acid, no N-acetyl cap, no C-terminal amide. The free N-terminal glycine is an aminopeptidase substrate; dipeptidyl peptidases take pairs off the same end; the Asp-Asp and Gly-Leu bonds are ordinary endopeptidase targets. The four prolines are the one structural feature working in its favor — proline resists many proteases and prolyl oligopeptidase is one of the few enzymes that handles those bonds — which is a plausible reason this peptide survives gastric juice better than most, and is not a reason it survives in plasma for hours.

The oral barrier. Oral bioavailability for a 1419 Da linear peptide is normally under 1% and is often unmeasurable. The gut wall presents both a brush-border peptidase layer and a tight-junction barrier a 1.4 kDa hydrophilic molecule does not cross by passive diffusion. The counter-argument specific to this compound is that its claimed native environment is gastric juice, and that much of the rodent gut work used oral or intragastric dosing and reported local effects — so an oral capsule may well be doing something to the gut without anything reaching plasma. Those are two different products with the same label.

The injectable comparator, and the arithmetic. A 250 mcg subcutaneous dose into roughly 5 L of plasma is about 50 ng/mL at complete and instantaneous absorption — a ceiling, not an estimate. With a 30-minute elimination half-life, that is down to about 6 ng/mL by 90 minutes and functionally gone inside 3 hours. Renal clearance of small peptide fragments finishes the job. Read against a twice-daily schedule, the molecule is absent from plasma for most of the day, which means any sustained effect has to be a downstream change the peptide triggered, not the peptide sitting there — consistent with a mechanism whose output is an enzyme being unclamped Hsieh 2020 rather than a receptor being occupied.

What would have to be true, and how you would know it was not

Three predictions fall out of the eNOS mechanism, and the first one is a real experiment nobody has run. The second cuts against the product.

1. Flow-mediated dilation should rise, and it is the single most direct human test this compound has. If BPC-157 releases eNOS from caveolin-1 in a person the way it does in rat aorta Hsieh 2020, then endothelium-dependent vasodilation should measurably improve. Flow-mediated dilation is exactly that measurement, it is non-invasive, and a brachial-artery FMD study before and at 4 weeks would settle in one arm whether the only demonstrated mechanism operates in humans at the doses people use. Hold ADMA — the endogenous eNOS inhibitor — constant across the window, because it moves FMD harder than this will, and do not compare a fasted morning scan to a post-meal one.

2. If the anti-inflammatory claim is real, hs-CRP and ESR should move; if they do not, the claim was about pain, not inflammation. This is the prediction that cuts against the product. People report BPC-157 relieving tendon and gut symptoms within days. Structural healing does not happen in days. So draw hs-CRP and ESR at baseline and at 4 weeks: if the symptom improvement is real tissue change you should see the inflammatory markers follow, and if the markers sit flat while the pain improves, the honest reading is symptomatic relief on a tissue that has not finished repairing — which is precisely the situation in which people re-injure themselves.

3. A CBC and a CMP should stay boring, and that is the point of drawing them. There is no published human toxicity signal, which is not the same as a clean safety record; it is an absence of looking. A CBC and a CMP before and after an 8-week run cost almost nothing and are the only systematic human safety data this compound will ever get, because nobody is going to fund the trial.

What nobody has tested yet

Four experiments that have never been run on this molecule and could be, listed because the people who could run them are the people reading this.

Nobody has ever measured endothelial function on BPC-157 in a human. Not once. The compound's only demonstrated mechanism is an endothelial one Hsieh 2020, flow-mediated dilation is a standard ultrasound measurement performed in thousands of trials, and the intersection of those two facts is empty. Twenty people with before-and-after FMD scans would produce more human mechanistic information about BPC-157 than currently exists.

Nobody has published a plasma concentration after an oral capsule. The oral product is sold at 250–500 mcg on the assumption that some fraction gets in. A single LC-MS/MS time course after one oral dose would either establish systemic absorption or establish that the oral form is a gut-local therapy — and either answer is more useful than the current silence.

Nobody has tested it against a placebo in a tendon. The clinically obvious trial — chronic Achilles or patellar tendinopathy, ultrasound tendon thickness and a validated pain score, 12 weeks — has never been reported. It is not an expensive trial. The absence is economic, not scientific.

Nobody has looked for the parent protein. The entire "body protection compound" framing predicts that human gastric juice contains a protein whose digestion yields this fifteen-residue run. Modern proteomics could confirm or refute that in a week, and doing so would either give the field a receptor to hunt for or retire a story that has been repeated for thirty years.

BPC-157 — its own safety story, not its class's

The class block above is about pro-angiogenic compounds in general. Here is what is specific to this one.

The interaction nobody lists, and it follows directly from the mechanism. The only demonstrated action of BPC-157 is releasing eNOS from caveolin-1 to generate nitric oxide Hsieh 2020. Nitrates donate NO. PDE5 inhibitors prevent the breakdown of the second messenger NO produces. Three agents converging on one pathway is the textbook setup for additive hypotension, and although this has never been tested in a person, the reasoning does not require a trial — it requires only that the rat-aorta result generalizes. Label this what it is: extrapolation from an isolated vessel preparation to a human taking two other vasodilators. It has not been observed, it has not been ruled out, and it is the sort of thing worth knowing before finding out.

The single-source problem is a safety problem, not just an efficacy one. When nearly all the animal work comes from one group Seiwerth 2021, the absence of reported adverse effects carries much less weight than the same absence across ten independent labs. Nothing here suggests the reports are wrong. It means the usual argument — "decades of animal work and no toxicity signal" — is weaker than it sounds.

The regulatory fact, stated accurately. The FDA moved BPC-157 to the bulk drug substances category 2 list in 2023, which restricts its use in compounding. Category 2 means significant safety risks have not been excluded on the available data. It is a statement about an evidence gap, and reading it either as a safety finding or as a bureaucratic irrelevance gets it wrong in opposite directions.

What the half-life means for risk. Under 30 minutes He 2022 means accumulation is not the failure mode here. The failure mode is doing too much on a tissue that feels better than it is, and there is no blood test for that.

Sources read for this page

• Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports 2020 · PMID 33051481
• Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology 2021 · PMID 34267654
• Brcic L, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology 2009 · PMID 20388964

BPC-157 — safety, predicted from mechanism

BPC-157 — interference & stacking

Bloodwork to run alongside BPC-157

Baseline first, then again at 8–12 weeks.

The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.

Check results you already have → · All 103 markers A–Z

BPC-157 — frequently asked questions

References & further reading

1. BPC-157 molecular mechanisms — cytoprotection, angiogenesis & nitric oxide (PMC, 2025)
2. BPC-157 and the Src–Caveolin-1–eNOS nitric-oxide pathway (PMC)
3. BPC-157 enhances growth-hormone-receptor expression in tendon fibroblasts (PMC)
4. BPC-157 human clinical trials — status & results (Peptide Database)
5. Legal status of BPC-157 in compounding & clinical practice (regulatory alert)

BPC-157 inside a finished plan

One arm of 4 Protocol Blueprints, free to read in full.

What BPC-157 is used for

BPC-157 appears under 5 goals in the goal router.

Related Healing & Recovery compounds

← Explore the full Protocol Vault

↑ Back to on this page